[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2828
66. Higgins SC, Pilkington GJ: The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res; 2010 Feb;30(2):391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma.
  • BACKGROUND: In this investigation the effects of tricyclic drugs on cellular respiration were studied using the anaplastic astrocytoma cell line IPSB-18 by use of a Clark-type oxygen electrode which measured changes in cellular respiration rate (oxygen consumption), in a dose-response assay.
  • Overall, it appeared that clomipramine and its metabolite norclomipramine were the most potent inhibitors of cellular respiration in glioma cells over the concentration range 0.5-0.9 mM.
  • Dexamethasone was able to induce inhibition of cellular respiration both alone in glioma cells, and in combination with clomipramine, where it had an additive or synergistic effect, thereby increasing cell death.
  • CONCLUSION: The extensive research currently ongoing and previously reported regarding the use of clomipramine as a potential antineoplastic agent aimed at targeting the mitochondria of gliomas is promising.
  • [MeSH-major] Antidepressive Agents, Tricyclic / pharmacology. Antineoplastic Agents, Hormonal / pharmacology. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Respiration / drug effects. Dexamethasone / pharmacology
  • [MeSH-minor] Amitriptyline / pharmacology. Antineoplastic Combined Chemotherapy Protocols. Clomipramine / pharmacology. Doxepin / pharmacology. Humans. Oxygen Consumption / drug effects. Respiratory Rate. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXEPIN .
  • Hazardous Substances Data Bank. Clomipramine .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. AMITRIPTYLINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332444.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; 0 / Antineoplastic Agents, Hormonal; 1668-19-5 / Doxepin; 1806D8D52K / Amitriptyline; 7S5I7G3JQL / Dexamethasone; NUV44L116D / Clomipramine
  •  go-up   go-down


67. Lee JM, Kim SH, Lee JI, Ryou JY, Kim SY: Acute comitant esotropia in a child with a cerebellar tumor. Korean J Ophthalmol; 2009 Sep;23(3):228-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute comitant esotropia in a child with a cerebellar tumor.
  • We report a case of acute comitant esotropia in a child with a cerebellar tumor.
  • A 3-year-old boy was referred for management of a 9 month history of acute acquired comitant esotropia.
  • The mass was completely excised and histological examination confirmed the diagnosis of pilocytic astrocytoma.
  • Therefore, acute onset comitant esotropia in a child can be the first sign of a cerebellar tumor, even without any other neurological signs and symptoms.
  • [MeSH-major] Astrocytoma / complications. Cerebellar Neoplasms / complications. Esotropia / etiology
  • [MeSH-minor] Acute Disease. Brain / pathology. Child, Preschool. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Oculomotor Muscles / surgery. Refraction, Ocular. Time Factors

  • Genetic Alliance. consumer health - Esotropia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Med Child Neurol. 1987 Apr;29(2):207-11 [3582790.001]
  • [Cites] Trans New Orleans Acad Ophthalmol. 1986;34:449-60 [3726963.001]
  • [Cites] Arch Ophthalmol. 1989 Mar;107(3):376-8 [2923560.001]
  • [Cites] Can J Ophthalmol. 1994 Jun;29(3):151-4 [7922858.001]
  • [Cites] Br J Ophthalmol. 1995 May;79(5):498-501 [7612566.001]
  • [Cites] Am J Ophthalmol. 1996 May;121(5):584-6 [8610811.001]
  • [Cites] J Neuroophthalmol. 1996 Mar;16(1):49-54 [8963421.001]
  • [Cites] Strabismus. 2004 Jun;12(2):119-23 [15672935.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1988;226(2):172-4 [3282996.001]
  • [Cites] J AAPOS. 1997 Sep;1(3):143-6 [10532775.001]
  • [Cites] Eye (Lond). 1999 Oct;13 ( Pt 5):617-20 [10696312.001]
  • [Cites] Int Ophthalmol. 1999;23(3):167-70 [11456255.001]
  • [Cites] Am J Ophthalmol. 1970 Apr;69(4):594-8 [5309572.001]
  • [Cites] Trans Am Ophthalmol Soc. 1970;68:730-822 [5524219.001]
  • [Cites] Br J Ophthalmol. 1972 Oct;56(10):776-82 [4679659.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1981 May-Jun;18(3):29-34 [7264848.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1987 Mar-Apr;24(2):83-6 [3585657.001]
  • (PMID = 19794955.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739968
  • [Keywords] NOTNLM ; Acute onset / Cerebellar tumor / Comitant esotropia
  •  go-up   go-down


68. Jin M, Komohara Y, Shichijo S, Yamanaka R, Nikawa J, Itoh K, Yamada A: Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci; 2008 Aug;99(8):1656-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients.
  • In the present study, we examined the expression of the EphB6 variant (EphB6v) in a panel of brain tumor cell lines and glioblastoma tissues and we found that EphB6v was preferentially expressed in malignant brain tumors, such as glioblastomas and anaplastic astrocytomas.
  • The two EphB6v-derived peptides exhibited the ability to bind to human leukocyte antigen (HLA)-A0201 molecules, and each of them was able to induce cytotoxic T lymphocytes in vitro in the peripheral blood mononuclear cells of HLA-A2(+) glioma patients.
  • [MeSH-minor] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Case-Control Studies. Cell Line, Tumor. Gene Expression. Glioblastoma / metabolism. HLA-A Antigens. HLA-A2 Antigen. Hepatocytes. Humans

  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754880.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; EC 2.7.1.- / EPHB6 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


69. Spacca B, Mallucci C, Riordan A, Appleton R, Thorp N, Pizer B: HSV encephalitis in a child with brain stem glioma: a rare complication of therapy. Case report and review of the neurosurgical literature. Childs Nerv Syst; 2007 Nov;23(11):1347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HSV encephalitis in a child with brain stem glioma: a rare complication of therapy. Case report and review of the neurosurgical literature.
  • CASE REPORT: A 13-year-old boy was diagnosed with an inoperable, biopsy-proven pontine grade II astrocytoma.
  • He made slow improvement but died 8 months after diagnosis from tumor progression.
  • [MeSH-major] Astrocytoma / complications. Brain Stem Neoplasms / complications. Encephalitis, Herpes Simplex / etiology. Herpesvirus 1, Human. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for brain stem glioma .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1972 Apr;36(4):499-502 [4335254.001]
  • [Cites] Hum Pathol. 1998 Mar;29(3):215-22 [9496822.001]
  • [Cites] Childs Nerv Syst. 1997 Jun;13(6):352-5 [9272290.001]
  • [Cites] Clin Infect Dis. 2003 May 15;36(10):1335-9 [12746782.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):239-42 [10407001.001]
  • [Cites] Herpes. 2004 Jun;11 Suppl 2:48A-56A [15319090.001]
  • [Cites] J Clin Microbiol. 1998 Aug;36(8):2229-34 [9665997.001]
  • [Cites] Antiviral Res. 2006 Sep;71(2-3):141-8 [16675036.001]
  • [Cites] J Virol. 1999 Dec;73(12):10514-8 [10559370.001]
  • [Cites] Neuroradiology. 1996 Jan;38(1):73-9 [8773284.001]
  • [Cites] Pediatr Neurol. 2003 Jul;29(1):69-71 [13679127.001]
  • [Cites] N Engl J Med. 1986 Jan 16;314(3):144-9 [3001520.001]
  • [Cites] Neurosurgery. 1999 Mar;44(3):633-5; discussion 635-6 [10069600.001]
  • [Cites] Herpes. 2004 Jun;11 Suppl 2:57A-64A [15319091.001]
  • (PMID = 17593375.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  • [Number-of-references] 14
  •  go-up   go-down


70. Darendeliler F, Karagiannis G, Wilton P, Ranke MB, Albertsson-Wikland K, Anthony Price D, On Behalf Of The Kigs International Board: Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr; 2006 Oct;95(10):1284-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database).
  • AIM: To analyse KIGS (Pfizer International Growth Database) with respect to tumour recurrence in patients with brain tumours.
  • METHODS: Data for tumour recurrence were analysed retrospectively in 1038 patients with craniopharyngiomas, 655 with medulloblastomas, 113 with ependymomas, 297 with germinomas, and 400 with astrocytomas or gliomas.
  • [MeSH-major] Brain Neoplasms / drug therapy. Human Growth Hormone / therapeutic use. Neoplasm Recurrence, Local / epidemiology. Recombinant Proteins / therapeutic use
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Craniopharyngioma / drug therapy. Craniopharyngioma / mortality. Craniopharyngioma / radiotherapy. Craniopharyngioma / surgery. Disease-Free Survival. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / radiotherapy. Ependymoma / surgery. Female. Germinoma / drug therapy. Germinoma / mortality. Germinoma / radiotherapy. Germinoma / surgery. Humans. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / radiotherapy. Medulloblastoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982503.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


71. Jaing TH, Lin KL, Tsay PK, Hsueh C, Hung PC, Wu CT, Tseng CK: Treatment of optic pathway hypothalamic gliomas in childhood: experience with 18 consecutive cases. J Pediatr Hematol Oncol; 2008 Mar;30(3):222-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of optic pathway hypothalamic gliomas in childhood: experience with 18 consecutive cases.
  • The aim of this study was to present our 17-year experience (1989 to 2006) in the treatment of optic pathway/hypothalamic gliomas (OPHG) in 18 children younger than 17 years (median age, 66 mo).
  • Histologic studies showed low-grade astrocytoma (WHO grade I or II) in 16 cases, anaplastic astrocytoma in 1, and oligoastrocytoma (WHO grade III) in 1.
  • Treatment included partial tumor resection in 12 patients, chemotherapy in 5, and radiotherapy in 3.
  • All treatment modalities led to tumor shrinkage and stabilization for a variable period, but none of them totally eradicated the tumor.
  • Fourteen (78%) of 18 patients had a sustained reduction of tumor size between 6 months and 17 years.
  • Two patients died, none with neurofibromatosis-1, with a hypothalamic/chiasmatic tumor with suprasellar extension and accompanying electrolyte abnormalities.
  • Because progression of these tumors is slow and associated with endocrinopathy, we recommend chemotherapy as a primary treatment of OPHG if the disease progresses.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypothalamic Neoplasms / therapy. Optic Nerve Glioma / therapy. Visual Pathways / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Predictive Value of Tests. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376285.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Pfister S, Witt O: Pediatric gliomas. Recent Results Cancer Res; 2009;171:67-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric gliomas.
  • Pediatric gliomas comprise a clinically, histologically, and molecularly very heterogeneous group of CNS tumors.
  • In addition, these tumors are largely different from their counterparts occurring in adults, although they are histologically indistinguishable and uniformly classified by the current WHO classification for CNS tumors.
  • Pilocytic astrocytoma (WHO grade I), mainly arising in the posterior fossa, is the most common representative in children, whereas glioblastoma multiforme (WHO grade IV) predominates in adults.
  • When radical surgical resection is possible in low-grade gliomas, it will likely cure the patient.
  • If complete surgical resection is not possible, however, for example in brainstem gliomas, which are defined by their anatomic localization rather than by their histological or molecular features, therapeutic options are limited and prognosis is usually poor.
  • Mitogen-activated protein kinase (MAPK) and PI3K/AKT signaling were identified as prominent oncogenic pathways in astrocytic tumors in several studies, whereas NOTCH signaling was implicated in the pathogenesis of a subset of intracranial ependymomas.
  • Future therapeutic strategies targeting these (and other) pathways or conferring epigenetic modifications in the tumor might contribute to a better treatment outcome of patients with unresectable or disseminated tumors at diagnosis.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322538.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 59
  •  go-up   go-down


73. Mamedova L, Capra V, Accomazzo MR, Gao ZG, Ferrario S, Fumagalli M, Abbracchio MP, Rovati GE, Jacobson KA: CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem Pharmacol; 2005 Dec 19;71(1-2):115-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1321N1 astrocytoma cells stably expressing human P2Y(1,2,4,6) receptors, CysLT1 antagonists inhibited both the P2Y agonist-induced activation of phospholipase C and intracellular Ca2+ mobilization.
  • In control astrocytoma cells expressing an endogenous M3 muscarinic receptor, 10 microM montelukast had no effect on the carbachol-induced rise in intracellular Ca2+.

  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - P2Y6 receptor - data and references .
  • Hazardous Substances Data Bank. MONTELUKAST .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280122.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 DK031116-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acetates; 0 / Chromones; 0 / DNA Primers; 0 / Membrane Proteins; 0 / Quinolines; 0 / Receptors, Leukotriene; 0 / Receptors, Purinergic P2; 0 / leukotriene D4 receptor; 0 / pranlukast; MHM278SD3E / montelukast; SY7Q814VUP / Calcium; UT0S826Z60 / Uridine Triphosphate
  • [Other-IDs] NLM/ NIHMS31385; NLM/ PMC4967539
  •  go-up   go-down


7
Advertisement
4. McNatt SA, Gonzalez-Gomez I, Nelson MD, McComb JG: Synchronous multicentric pleomorphic xanthoastrocytoma: case report. Neurosurgery; 2005 Jul;57(1):E191; discussion E191
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE AND IMPORTANCE: Pleomorphic xanthoastrocytoma (PXA) is a rare, low-grade astrocytoma of adolescence.
  • INTERVENTION: A right frontal craniotomy was performed for excisional biopsy of a superficial lesion beneath the coronal suture.
  • Three years after treatment, the patient remains neurologically nonfocal and shows no evidence of disease progression.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987556.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Harder T, Plagemann A, Harder A: Birth weight and subsequent risk of childhood primary brain tumors: a meta-analysis. Am J Epidemiol; 2008 Aug 15;168(4):366-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have suggested that high birth weight is associated with an increased brain tumor risk.
  • The authors identified eight studies involving 1,748,964 children, of whom 4,162 suffered from brain tumors of three histologic types (astrocytoma, medulloblastoma, and ependymoma).
  • For astrocytoma, high birth weight (>4,000 g) was associated with increased risk (odds ratio = 1.38, 95% confidence interval (CI): 1.07, 1.79), with each 1,000-g increase in birth weight being associated with a 19% (95% CI: 4, 36) increase in risk.
  • [MeSH-major] Astrocytoma / epidemiology. Birth Weight. Brain Neoplasms / epidemiology. Ependymoma / epidemiology. Fetal Macrosomia / epidemiology. Medulloblastoma / epidemiology

  • MedlinePlus Health Information. consumer health - Birth Weight.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579539.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


76. Durmaz R, Vural M, Işildi E, Coşan E, Ozkara E, Bal C, Ciftçi E, Arslantaş A, Atasoy MA: Efficacy of prognostic factors on survival in patients with low grade glioma. Turk Neurosurg; 2008 Oct;18(4):336-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of prognostic factors on survival in patients with low grade glioma.
  • AIM: In this report, we aim to determine the prognostic factors influencing the length of survival in patients with low-grade gliomas.
  • The diagnoses of the patients were histopathologically verified as low-grade glioma(LGG).
  • The medical records of the patients were reviewed for age, gender, tumor locations, extent of resection, and presence of seizure, the neurological status as defined by the Karnofsky Performance Scale (KPS) and radiotherapy treatment after surgery as possible prognostic factors.
  • Median survival time was 216+/-78.52 months for astrocytoma Grade I; 115+/-8.22 months for astrocytoma Grade II, and 242+/-76.36 months for oligodendroglioma.
  • Young age, histology subtype (oligodendroglioma) and preoperative KPS were determined to have positive influence on survival according to Log Rank Test.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Glioma / mortality. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aging. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Oligodendroglioma / mortality. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Prognosis. Reoperation. Retrospective Studies. Seizures / etiology. Survival. Tomography, X-Ray Computed. Young Adult


77. Stark AM, Fritsch MJ, Claviez A, Dörner L, Mehdorn HM: Management of tectal glioma in childhood. Pediatr Neurol; 2005 Jul;33(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of tectal glioma in childhood.
  • Tectal glioma is a topographical diagnosis including tumors of different histology, mainly low-grade astrocytomas.
  • This report discusses the management of this rare tumor in children.
  • Clinical charts of 12 children with tectal glioma treated in our department between 1976 and 2001 were retrospectively reviewed.
  • The duration between first symptoms and the diagnosis of tectal glioma was in the range of 2 days to 9 years.
  • Ten patients presented with symptoms associated with increased intracranial pressure, one patient presented with ataxia, and in one case tectal glioma was an incidental finding.
  • First-line therapy was endoscopic third ventriculostomy in 5 cases (42%), ventriculoperitoneal shunting in 6 cases (50%), and combined partial tumor resection and shunting in one case.
  • Histology was obtained in 5 cases (low-grade astrocytoma, n = 4; ependymoma, n = 1).
  • Tectal glioma represents a distinct subgroup of brainstem tumors associated with a good (or favorable) prognosis.
  • Effective treatment for hydrocephalus is essential; the tumor should be monitored by regular clinical examination and magnetic resonance imaging.
  • Biopsy is warranted in cases with tumor progression.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / therapy. Glioma / pathology. Glioma / therapy. Superior Colliculi / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Management. Female. Follow-Up Studies. Humans. Infant. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876519.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Shimizu H, Mori O, Ohaki Y, Kamoi S, Kobayashi S, Okada S, Maeda S, Naito Z: Cytological interface of diffusely infiltrating astrocytoma and its marginal tissue. Brain Tumor Pathol; 2005;22(2):59-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological interface of diffusely infiltrating astrocytoma and its marginal tissue.
  • Cytological differences between infiltrating lesions of the diffusely infiltrating astrocytoma (DIA) and reactive gliosis at its periphery have not yet been established.
  • The cytological findings of this area are important because the surgeon may have to make a rapid diagnosis regarding the existence of the tumor.
  • [MeSH-major] Astrocytoma / pathology. Brain / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology. Gliosis / pathology
  • [MeSH-minor] Adult. Astrocytes / ultrastructure. Axons / ultrastructure. Biopsy. Carcinoma / secondary. Cell Nucleus / ultrastructure. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Myelin Sheath / ultrastructure. Neoplasm Invasiveness. Neurons / ultrastructure. Oligodendroglia / ultrastructure. Staining and Labeling / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095107.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


79. Server A, Kulle B, Maehlen J, Josefsen R, Schellhorn T, Kumar T, Langberg CW, Nakstad PH: Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema. Acta Radiol; 2009 Jul;50(6):682-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Conventional magnetic resonance (MR) imaging has a number of limitations in the diagnosis of the most common intracranial brain tumors, including tumor specification and the detection of tumoral infiltration in regions of peritumoral edema.
  • PURPOSE: To prospectively assess if diffusion-weighted MR imaging (DWI) could be used to differentiate between different types of brain tumors and to distinguish between peritumoral infiltration in high-grade gliomas, lymphomas, and pure vasogenic edema in metastases and meningiomas.
  • MATERIAL AND METHODS: MR imaging and DWI was performed on 93 patients with newly diagnosed brain tumors: 59 patients had histologically verified high-grade gliomas (37 glioblastomas multiforme, 22 anaplastic astrocytomas), 23 patients had metastatic brain tumors, five patients had primary cerebral lymphomas, and six patients had meningiomas.
  • Apparent diffusion coefficient (ADC) values of tumor (enhancing regions or the solid portion of tumor) and peritumoral edema, and ADC ratios (ADC of tumor or peritumoral edema to ADC of contralateral white matter, ADC of tumor to ADC of peritumoral edema) were compared with the histologic diagnosis.
  • ADC values and ratios of high-grade gliomas, primary cerebral lymphomas, metastases, and meningiomas were compared by using ANOVA and multiple comparisons.
  • Optimal thresholds of ADC values and ADC ratios for distinguishing high-grade gliomas from metastases were determined by receiver operating characteristic (ROC) curve analysis.
  • RESULTS: Statistically significant differences were found for minimum and mean of ADC tumor and ADC tumor ratio values between metastases and high-grade gliomas when including only one factor at a time.
  • Including a combination of in total four parameters (mean ADC tumor, and minimum, maximum and mean ADC tumor ratio) resulted in sensitivity, specificity, positive (PPV), and negative predictive values (NPV) of 72.9, 82.6, 91.5, and 54.3% respectively.
  • CONCLUSION: Our results suggest that ADC values and ADC ratios (minimum and mean of ADC tumor and ADC tumor ratio) may be helpful in the differentiation of metastases from high-grade gliomas.
  • It cannot distinguish high-grade gliomas from lymphomas, and lymphomas from metastases.
  • ADC values and ADC ratios in peritumoral edema cannot be used to differentiate edema with infiltration of tumor cells from vasogenic edema when measurements for high-grade gliomas, lymphomas, metastases, and meningiomas were compared.
  • [MeSH-major] Brain Edema / pathology. Brain Neoplasms / pathology. Glioma / pathology. Lymphoma / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19449234.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Yang X, Cao W, Lin H, Zhang W, Lin W, Cao L, Zhen H, Huo J, Zhang X: Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci; 2009 Jan 15;276(1-2):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isoform-specific expression of 14-3-3 proteins in human astrocytoma.
  • In the present study, the levels of all seven 14-3-3 isoforms were examined in astrocytoma.
  • METHODS: The expression of 14-3-3 isoforms and their protein expression levels were examined in five glioma cell lines by western blotting.
  • Then in astrocytoma tissues, we investigated expression percentages of each isoform by immunohistochemistry.
  • RESULTS: 14-3-3beta and eta were specifically expressed in astrocytoma, and their expression frequencies and levels increased with the increase of astrocytoma malignancy.
  • The result from glioma cell lines was consistent with that from astrocytoma tissue.
  • CONCLUSIONS: In our study, we found two tumor-specific isoforms of 14-3-3 in astrocytoma.
  • They might be involved in astrocytoma tumorigenesis and may be useful as targets for therapy.
  • [MeSH-major] 14-3-3 Proteins / metabolism. Astrocytoma / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18851859.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


81. Amin A, Monabati A, Kumar PV, Hashemi SB: Nasal glioma (neuroglial heterotopia) mimicking an astrocytoma: case report. Ear Nose Throat J; 2005 Oct;84(10):657-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal glioma (neuroglial heterotopia) mimicking an astrocytoma: case report.
  • Nasal glioma is a rare benign tumor that usually occurs during infancy.
  • We report a case of nasal glioma in a 6-month-old boy in which the histomorphologic features resembled those of an anaplastic astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Glioma / diagnosis. Neuroglia / pathology. Nose Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382748.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Andreiuolo F, Junier MP, Hol EM, Miquel C, Chimelli L, Leonard N, Chneiweiss H, Daumas-Duport C, Varlet P: GFAPdelta immunostaining improves visualization of normal and pathologic astrocytic heterogeneity. Neuropathology; 2009 Feb;29(1):31-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GFAPdelta immunostaining improves visualization of normal and pathologic astrocytic heterogeneity.
  • We therefore evaluated GFAPdelta immunostaining in a wide panel of astrogliosis and gliomas, and compared these with GFAP and vimentin.
  • In normal tissue, gliosis and gliomas, GFAPdelta immunostaining was observed in astrocytes with relatively high GFAP levels.
  • Interestingly GFAPdelta and vimentin immunostainings coincided in normal tissues and gliosis, but not in gliomas.
  • [MeSH-major] Astrocytes / cytology. Astrocytes / pathology. Brain Diseases / pathology. Brain Neoplasms / pathology. Glial Fibrillary Acidic Protein / analysis. Glioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564099.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  •  go-up   go-down


83. Nafe R, Schlote W, Schneider B: Histomorphometry of tumour cell nuclei in astrocytomas using shape analysis, densitometry and topometric analysis. Neuropathol Appl Neurobiol; 2005 Feb;31(1):34-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histomorphometry of tumour cell nuclei in astrocytomas using shape analysis, densitometry and topometric analysis.
  • Although tumour cell nuclei are important histological structures for grading of astrocytomas according to the WHO-classification of brain tumours, there is no reported morphometric study of astrocytomas which describes quantitatively the four main morphologic criteria of tumour cell nuclei: size, shape, texture (densitometric characteristics) and spatial relationships between the nuclei (topometric analysis).
  • Using a set of morphometric parameters describing these criteria as well as the Ki67-proliferation index, 74 astrocytomas from 74 patients were studied by means of a digital image analysis system.
  • The objective of the study was to test, if these morphometric parameters were sufficient for statistical discrimination between pilocytic astrocytomas WHO-grade I, astrocytomas grade II and anaplastic astrocytomas grade III.
  • In conclusion, the present morphometric procedure provided good discrimination between the tumour grades, supporting the view that histomorphometry of tumour cell nuclei could be a valuable tool for grading of astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / ultrastructure. Brain Neoplasms / pathology. Brain Neoplasms / ultrastructure. Cell Nucleus / pathology. Cell Nucleus / ultrastructure

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15634229.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Endale M, Kim SD, Lee WM, Kim S, Suk K, Cho JY, Park HJ, Wagley Y, Kim S, Oh JW, Rhee MH: Ischemia induces regulator of G protein signaling 2 (RGS2) protein upregulation and enhances apoptosis in astrocytes. Am J Physiol Cell Physiol; 2010 Mar;298(3):C611-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the role of ischemic stress in RGS2 protein expression in rat C6 astrocytoma cells and primary mouse astrocytes.
  • [MeSH-minor] Animals. Caspase 3 / metabolism. Cell Hypoxia. Cell Line, Tumor. Glucose / deficiency. Humans. Mice. Oxidative Stress. Phosphorylation. Protein Kinase C-delta / antagonists & inhibitors. Protein Kinase C-delta / genetics. Protein Kinase C-delta / metabolism. Protein Kinase Inhibitors / pharmacology. RNA Interference. RNA, Messenger / metabolism. Rats. Recombinant Fusion Proteins / metabolism. Signal Transduction. Time Factors. Transfection. Up-Regulation. p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors. p38 Mitogen-Activated Protein Kinases / metabolism

  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032508.001).
  • [ISSN] 1522-1563
  • [Journal-full-title] American journal of physiology. Cell physiology
  • [ISO-abbreviation] Am. J. Physiol., Cell Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / RGS Proteins; 0 / RGS2 protein, human; 0 / RGS2 protein, rat; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 0 / Rgs2 protein, mouse; EC 2.7.11.13 / Protein Kinase C-delta; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspase 3; IY9XDZ35W2 / Glucose
  •  go-up   go-down


85. Narayana A, Bhatia S, Souweidane M, Khakoo Y, Zaider M: (32)P radioisotope therapy for recurrent pilocytic astrocytoma. Brachytherapy; 2005;4(2):171-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (32)P radioisotope therapy for recurrent pilocytic astrocytoma.
  • Its effectiveness in the treatment of a selected brain tumor is illustrated here.
  • [MeSH-major] Astrocytoma / radiotherapy. Basal Ganglia / pathology. Brachytherapy / methods. Brain Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Phosphorus Radioisotopes / therapeutic use


86. Holland H, Koschny T, Ahnert P, Meixensberger J, Koschny R: WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis. Pathol Res Pract; 2010 Oct 15;206(10):663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WHO grade-specific comparative genomic hybridization pattern of astrocytoma - a meta-analysis.
  • To detect novel genetic alterations, many astrocytomas have been investigated by comparative genomic hybridization (CGH).
  • To identify aberration profiles characteristic of World Health Organization (WHO) grade I, II, III, and IV astrocytoma, we performed a meta-analysis of detailed genome wide CGH data of all 467 cases published so far.
  • Low-grade astrocytoma has already demonstrated one characteristic of glioblastoma multiforme, gain of chromosome 7 with a hot spot at 7q32, but without loss of chromosome 10.
  • In anaplastic astrocytoma, a more complex aberration pattern emerges from diffuse genetic imbalances.
  • In contrast to lower tumor grades, glioblastoma multiforme demonstrates +7p12 as the most frequently affected band on chromosome 7.
  • To quantify the gradual transition from WHO grade II-IV astrocytoma, we calculated the relative increase and decrease in frequency for each detected aberration of the tumor genome.
  • The most pronounced and diverse changes of genetic material occur at the virtual transition from low-grade to anaplastic astrocytoma.
  • Summing up, the expansion of the CGH results to the 850 GTG-band resolution enabled a meta-analysis to visualize WHO grade-specific aberration profiles in astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Comparative Genomic Hybridization. Glioblastoma / genetics. World Health Organization
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Genotype. Humans. Neoplasm Staging. Phenotype. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20570053.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Germany
  •  go-up   go-down


87. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet; 2005 Sep 17-23;366(9490):985-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
  • BACKGROUND: Postoperative policies of "wait-and-see" and radiotherapy for low-grade glioma are poorly defined.
  • In 1986 the EORTC Radiotherapy and Brain Tumor Groups initiated a prospective trial to compare early radiotherapy with delayed radiotherapy.
  • Patients with low-grade astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and incompletely resected pilocytic astrocytoma, with a WHO performance status 0-2 were eligible.
  • Radiotherapy could be deferred for patients with low-grade glioma who are in a good condition, provided they are carefully monitored.
  • [MeSH-major] Astrocytoma / radiotherapy. Central Nervous System Neoplasms / radiotherapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Dec;6(12):921; author reply 922 [16321759.001]
  • [ErratumIn] Lancet. 2006 Jun 3;367(9525):1818
  • (PMID = 16168780.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-; United States / NCI NIH HHS / CA / 5U10 CA11488-16
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


88. Li B, Qi XQ, Chen X, Huang X, Liu GY, Chen HR, Huang CG, Luo C, Lu YC: Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. Brain Res; 2010 Sep 17;1352:200-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma.
  • However, the contribution of TPX2 expression to astrocytoma progression is unclear.
  • The aim of this study was to investigate TPX2 expression in human astrocytoma samples and cell lines.
  • TPX2 protein expression was detected in the nucleus of astrocytoma tissues by immunohistochemistry and immunofluorescence staining.
  • Real-time PCR and Western blot analysis showed that the expression levels of TPX2 were higher in high-grade astrocytoma tissues and cell lines than that in low-grade astrocytoma tissues and normal cell lines.
  • Immunohistochemical analysis of tumor tissues from 52 patients with astrocytoma showed that TPX2 over-expression was significantly associated with decreased patient survival.
  • These data suggest that TPX2 expression is associated with the progression of malignant astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Cell Cycle Proteins / genetics. Microtubule-Associated Proteins / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Apoptosis. Aurora Kinases. Brain / metabolism. Cell Division. Cell Line, Tumor. Cyclin B1 / genetics. Cyclin D1 / genetics. Disease Progression. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Protein-Serine-Threonine Kinases / genetics. Proto-Oncogene Proteins c-myc / genetics. Survival Rate. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20599806.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin B1; 0 / Microtubule-Associated Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / TPX2 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


89. Ohta K, Kuwahara K, Zhang Z, Makino K, Komohara Y, Nakamura H, Kuratsu J, Sakaguchi N: Decreased expression of germinal center-associated nuclear protein is involved in chromosomal instability in malignant gliomas. Cancer Sci; 2009 Nov;100(11):2069-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of germinal center-associated nuclear protein is involved in chromosomal instability in malignant gliomas.
  • Malignant glioma (MG) is highly proliferative and invasive, with the malignant characteristics associated with aneuploidy and chromosomal instability (CIN).
  • Glioblastomas showed a significantly lower level of ganp mRNA than anaplastic astrocytomas, as measured by real-time reverse transcription-PCR, in 101 cases of adult MG.
  • [MeSH-major] Acetyltransferases / physiology. Brain Neoplasms / genetics. Chromosomal Instability. Glioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Cycle. Cell Line, Tumor. Cell Proliferation. Female. Genes, p53. Humans. Intracellular Signaling Peptides and Proteins. Loss of Heterozygosity. Male. Middle Aged. Mutation. RNA Interference. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19686285.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / MCM3AP protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


90. Montemor JP, Peria FM, Monti CR, Petrilli LS, Colli BO, Carlotti Júnior CG: Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment. Onkologie; 2008 Sep;31(8-9):435-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with weekly paclitaxel in malignant cerebral glioma treatment.
  • BACKGROUND: Anaplastic astrocytomas (AA) and glioblastomas (GB) are the most common malignant gliomas, and despite newly developed drugs and combined treatments, they still have an adverse prognosis.
  • Paclitaxel is a cytotoxic agent with radiosensitizing properties and exerts objective growth inhibition in glioma tumor cells.
  • CONCLUSIONS: Chemoradiotherapy with weekly paclitaxel is safe and tolerable although there was no increase in the overall survival and 12-month survival of malignant glioma patients.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18787350.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


91. Ikota H, Kinjo S, Yokoo H, Nakazato Y: Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol; 2006 May;111(5):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our TMA consisted of a grid of 1.5-mm cores that were extracted from individual donor blocks.
  • Ten antibodies [glial fibrillary acidic protein (GFAP), Olig2, vimentin, epithelial membrane antigen (EMA), cytokeratin (AE1/AE3), alpha-internexin, nestin, pinealocytes PP5, aquaporin-4 (AQP4) M13d and AQP4M13e] discriminated between astrocytomas and oligodendroglial tumors.
  • Six antibodies [EMA, AE1/AE3, TUJ1, nestin, neurofilament protein-MH (NF-MH) and perivascular cells GP-1] showed significant differences between high-grade and low-grade gliomas.
  • Our data have revealed new antibodies with potential diagnostic utility (Olig2, PP5, GP-1) and demonstrate that TMA technology is highly useful for evaluating newly established antibodies in brain-tumor research.
  • [MeSH-major] Antibodies / immunology. Astrocytoma / immunology. Brain Neoplasms / immunology. Immunohistochemistry / methods. Oligodendroglioma / immunology. Protein Array Analysis / methods
  • [MeSH-minor] Aquaporin 4 / immunology. Aquaporin 4 / metabolism. Basic Helix-Loop-Helix Transcription Factors / immunology. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Cluster Analysis. Diagnosis, Differential. Glial Fibrillary Acidic Protein / immunology. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / immunology. Intermediate Filament Proteins / metabolism. Mucin-1 / immunology. Mucin-1 / metabolism. Nerve Tissue Proteins / immunology. Nerve Tissue Proteins / metabolism. Nestin. Prognosis. Vimentin / immunology. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598485.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Antibodies; 0 / Aquaporin 4; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Mucin-1; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / OLIG2 protein, human; 0 / Vimentin; 0 / alpha-internexin
  •  go-up   go-down


92. Kitis O, Altay H, Calli C, Yunten N, Akalin T, Yurtseven T: Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol; 2005 Sep;55(3):393-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine whether diffusion-weighted imaging by using minimum apparent diffusion coefficient (ADC(min)) values could differentiate various brain tumors including gliomas, metastases, and lymphomas.
  • MATERIALS AND METHODS: We examined 65 patients with histologically or clinically diagnosed brain tumors (12 low-grade gliomas, 31 high-grade gliomas, 14 metastatic tumors, and 8 lymphomas) using a 1.5 T MR unit.
  • RESULTS: The ADC(min) values of low-grade gliomas (1.09+/-0.20 x 10(-3)mm(2)/s) were significantly higher (p<.001) than those of other tumors.
  • There were no statistical significant differences between glioblastomas (0.70+/-0.16 mm(2)/s), anaplastic astrocytomas (0.77+/-0.21 mm(2)/s), metastases (0.78+/-0.21 mm(2)/s), and lymphomas.
  • But, lymphomas had lower mean ADC(min) values (0.54+/-0.10mm(2)/s) than high-grade gliomas and metastases.
  • CONCLUSION: The ADC measurements may help to differentiate low-grade gliomas from high-grade gliomas, metastases, and lymphomas.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Diagnosis, Differential. Female. Glioma / pathology. Humans. Lymphoma / pathology. Male. Middle Aged. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129247.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


93. Bajenaru ML, Garbow JR, Perry A, Hernandez MR, Gutmann DH: Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. Ann Neurol; 2005 Jan;57(1):119-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of neurofibromatosis 1-associated optic nerve glioma in mice.
  • Children affected with the inherited tumor predisposition syndrome, neurofibromatosis 1 (NF1), are prone to the development of low-grade astrocytic optic pathway tumors (optic pathway glioma [OPG]).
  • Previously, we developed a model of NF1-associated astrocytoma (GFAPCre; Nf1(flox/mut) mice) in which mice develop optic nerve and chiasm glioma.
  • Last, we observed neovascularization and microglial cell infiltration by 3 weeks of age before overt neoplastic transformation, suggesting that these cellular changes participate in the early stages of tumor formation.
  • [MeSH-major] Glioma / complications. Neurofibromatosis 1 / complications. Optic Nerve Neoplasms / complications
  • [MeSH-minor] Age Factors. Animals. Animals, Newborn. Antigens / metabolism. Blood Vessels / physiology. Disease Models, Animal. Glial Fibrillary Acidic Protein / metabolism. Immunohistochemistry / methods. Indoles / metabolism. Intermediate Filament Proteins / metabolism. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging / methods. Mice. Mice, Transgenic. Nerve Tissue Proteins / metabolism. Nestin. Staining and Labeling / methods. von Willebrand Factor / immunology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622533.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R24 CA 83060; United States / NEI NIH HHS / EY / 5T32 EY 13360-03; United States / NINDS NIH HHS / NS / NS 36996; United States / NCI NIH HHS / CA / P30 CA 91842
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Glial Fibrillary Acidic Protein; 0 / Indoles; 0 / Intermediate Filament Proteins; 0 / Ki-67 Antigen; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Von Willebrand antigen; 0 / von Willebrand Factor; 47165-04-8 / DAPI
  •  go-up   go-down


94. Morales H, Kwock L, Castillo M: Magnetic resonance imaging and spectroscopy of pilomyxoid astrocytomas: case reports and comparison with pilocytic astrocytomas. J Comput Assist Tomogr; 2007 Sep-Oct;31(5):682-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging and spectroscopy of pilomyxoid astrocytomas: case reports and comparison with pilocytic astrocytomas.
  • BACKGROUND AND PURPOSE: Pilomyxoid astrocytomas (PMAs) have been described only recently.
  • They appear as low-grade tumors sharing imaging features similar to pilocytic astrocytomas (PAs).
  • However, pilomyxoid astrocytomas have different histological features and behave more aggressively than PAs.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Myxoma / metabolism. Myxoma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895777.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4L6452S749 / Inositol; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


95. Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL: Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther; 2006 Dec;13(12):1052-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma.
  • We performed a phase I clinical trial in grade IV astrocytoma to assess the safety of a whole-cell vaccine comprising autologous tumor cells genetically modified by a transforming growth factor-beta2 (TGF-beta2) antisense vector.
  • Blocking secretion of the immunosuppressive molecule TGF-beta in this manner should inhibit one of the major mechanisms by which tumor cells evade immune surveillance and should lead to clinically effective antitumor immunity.
  • Six patients with progressive WHO grade IV astrocytoma were enrolled in the trial.
  • Patients received 2-7 subcutaneous injections of 5 x 10(6)-2 x 10(7) autologous tumor cells per injection.
  • TGF-beta2 secretion by the tumor cells used to vaccinate patients was inhibited by 53-98%.
  • Two patients had partial regressions and two had stable disease following therapy.
  • Median survival of the responding patients was 78 weeks, compared to a historic value of 47 weeks for glioma patients treated conventionally.
  • These findings support further clinical evaluation of vaccines comprised of TGF-beta antisense-modified tumor cells.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Central Nervous System Neoplasms / drug therapy. Glioma / drug therapy. Oligonucleotides, Antisense / genetics. Transforming Growth Factor beta2 / genetics
  • [MeSH-minor] Adult. Antibody Formation. Female. Humans. Injections, Intradermal. Male. Middle Aged. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826191.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA105964; United States / NCI NIH HHS / CA / CA96025
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Oligonucleotides, Antisense; 0 / Transforming Growth Factor beta2
  •  go-up   go-down


96. Opstad KS, Bell BA, Griffiths JR, Howe FA: Taurine: a potential marker of apoptosis in gliomas. Br J Cancer; 2009 Mar 10;100(5):789-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taurine: a potential marker of apoptosis in gliomas.
  • Magnetic resonance spectroscopy (MRS) can determine the tumour biochemical profile in vivo, and we have investigated whether a specific spectroscopic signature exists for apoptosis in human astrocytomas.
  • Metabolites, mobile lipids and macromolecules were quantified from presaturation HRMAS (1)H spectra acquired from 41 biopsies of grades II (n=8), III (n=3) and IV (n=30) astrocytomas.
  • We suggest that the taurine (1)H MRS signal in astrocytomas may be a robust apoptotic biomarker that is independent of tumour necrotic status.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Taurine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Nov;5(11):1323-7 [10546002.001]
  • [Cites] NMR Biomed. 2008 Nov;21(10):1138-47 [18666093.001]
  • [Cites] Pflugers Arch. 2000 May;440(1):93-9 [10864002.001]
  • [Cites] NMR Biomed. 2000 May;13(3):129-53 [10861994.001]
  • [Cites] Bioessays. 2000 Nov;22(11):1007-17 [11056477.001]
  • [Cites] Magn Reson Med. 2001 Mar;45(3):409-14 [11241697.001]
  • [Cites] Biochim Biophys Acta. 2001 Jan 15;1530(1):47-66 [11341958.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1394-400 [11888911.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):963-70 [11953830.001]
  • [Cites] Toxicol Pathol. 2002 Sep-Oct;30(5):541-51 [12371662.001]
  • [Cites] Microsc Microanal. 2002 Oct;8(5):375-91 [12533214.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3195-201 [12810648.001]
  • [Cites] NMR Biomed. 2003 Jun;16(4):199-212 [14558118.001]
  • [Cites] Biochim Biophys Acta. 2003 Oct 20;1634(1-2):1-14 [14563408.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1307-11 [14648580.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):824-9; discussion 829 [15458590.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):595-604 [15497113.001]
  • [Cites] J Neurochem. 1981 Feb;36(2):406-10 [7463068.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Lab Invest. 1994 Aug;71(2):219-25 [8078301.001]
  • [Cites] J Neurochem. 1994 Oct;63(4):1538-43 [7931308.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):407-14 [9012466.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1825-32 [9581820.001]
  • [Cites] Magn Reson Med. 1999 Sep;42(3):454-60 [10467289.001]
  • [Cites] Biochim Biophys Acta. 2005 May 1;1734(1):1-12 [15866478.001]
  • [Cites] Magn Reson Med. 2005 Jul;54(1):43-50 [15968678.001]
  • [Cites] J Physiol. 2005 Sep 1;567(Pt 2):427-43 [15975986.001]
  • [Cites] BMC Cancer. 2007;7:11 [17233882.001]
  • [Cites] NMR Biomed. 2008 Aug;21(7):677-85 [18186027.001]
  • [Cites] Magn Reson Med. 2008 Nov;60(5):1237-42 [18836999.001]
  • [Cites] Pflugers Arch. 2000 Jan;439(3):271-7 [10650978.001]
  • (PMID = 19223899.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / C1459/A2592
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1EQV5MLY3D / Taurine
  • [Other-IDs] NLM/ PMC2653765
  •  go-up   go-down


97. Greco Crasto S, Soffietti R, Rudà R, Cassoni P, Ducati A, Davini O, De Lucchi R, Rizzo L: Diffusion-Weighted Magnetic Resonance Imaging and ADC Maps in the Diagnosis of Intracranial Cystic or Necrotic Lesions. A Retrospective Study on 49 Patients. Neuroradiol J; 2007 Dec 31;20(6):666-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven tumours (11/44) appeared hyperintense on DWI: eight metastases from lung cancer (mean ADC value 0.86 mm(2)/s, range 0.75-1.2 mm(2)/s), two GBMs (mean 0.7 mm(2)/s, range 0.67-0.76 mm(2)/s) and one anaplastic astrocytoma (ADC value 1.24 mm(2)/s).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24300002.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Harris LM, Davies N, Macpherson L, Foster K, Lateef S, Natarajan K, Sgouros S, Brundler MA, Arvanitis TN, Grundy RG, Peet AC: The use of short-echo-time 1H MRS for childhood cerebellar tumours prior to histopathological diagnosis. Pediatr Radiol; 2007 Nov;37(11):1101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peak heights for N-acetyl aspartate (NAA), creatine (Cr), choline (Cho) and myo-inositol (mIns) were determined and receiver operator characteristic curves used to select ratios that best discriminated between the tumour types.
  • NAA/Cr >4.0 distinguished all but one of the astrocytomas from the other tumours.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Biomarkers, Tumor / analysis. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / metabolism. Choline / analysis. Creatine / analysis. Inositol / analysis. Magnetic Resonance Spectroscopy / methods

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Mar 15;100(6):1246-56 [15022293.001]
  • [Cites] Comput Biol Med. 2001 Jul;31(4):269-86 [11334636.001]
  • [Cites] J Magn Reson Imaging. 2006 Feb;23(2):99-107 [16374884.001]
  • [Cites] J Magn Reson. 2004 Sep;170(1):164-75 [15324770.001]
  • [Cites] Med Sci Monit. 2003 Sep;9(9):MT97-105 [12960934.001]
  • [Cites] J Neurooncol. 1999;45(1):69-81 [10728912.001]
  • [Cites] Radiology. 2005 Sep;236(3):1020-5 [16118174.001]
  • [Cites] NMR Biomed. 1997 May;10(3):99-124 [9408920.001]
  • [Cites] Magn Reson Med. 2005 Jan;53(1):22-9 [15690498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):20-31 [15850898.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1271-6 [11955739.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):560-72 [16551993.001]
  • [Cites] NeuroRx. 2005 Apr;2(2):197-214 [15897945.001]
  • [Cites] Oncologist. 2004;9(3):312-8 [15169986.001]
  • [Cites] Magn Reson Med. 2003 Jan;49(1):29-36 [12509817.001]
  • [Cites] Magn Reson Imaging. 2004 Sep;22(7):1017-24 [15288143.001]
  • [Cites] NMR Biomed. 1998 Jun-Aug;11(4-5):192-200 [9719573.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1020-6 [10694552.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1404-11 [16908548.001]
  • [Cites] Childs Nerv Syst. 2007 Feb;23(2):163-9 [17106750.001]
  • [Cites] Magn Reson Med. 2005 Dec;54(6):1333-9 [16265633.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):306-18 [10690719.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Oct;16(9):1821-33 [8693982.001]
  • [Cites] NMR Biomed. 1998 Jun-Aug;11(4-5):225-34 [9719577.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):497-507 [12748312.001]
  • [Cites] Magn Reson Med. 1993 Dec;30(6):672-9 [8139448.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] NMR Biomed. 2003 May;16(3):123-31 [12884355.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8220-8 [15623597.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1037-44 [17349783.001]
  • [Cites] NMR Biomed. 2004 Oct;17(6):361-81 [15468083.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):728-35 [12651196.001]
  • [Cites] NMR Biomed. 2006 Jun;19(4):411-34 [16763971.001]
  • (PMID = 17823793.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601327
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; 30KYC7MIAI / Aspartic Acid; 4L6452S749 / Inositol; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


99. Janzarik WG, Kratz CP, Loges NT, Olbrich H, Klein C, Schäfer T, Scheurlen W, Roggendorf W, Weiller C, Niemeyer C, Korinthenberg R, Pfister S, Omran H: Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics; 2007 Apr;38(2):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
  • Astrocytomas are the most common brain tumors of childhood.
  • However, knowledge of the molecular etiology of astrocytomas WHO grade I and II is limited.
  • Germline mutations in the Ras-guanosine triphosphatase-activating protein, neurofibromin, in individuals with neurofibromatosis type I predispose to pilocytic astrocytomas.
  • This association suggests that constitutive activation of the Ras signaling pathway plays a fundamental role in astrocytoma development.
  • We screened 25 WHO I and II astrocytomas for mutations of PTPN11, NRAS, KRAS, and HRAS genes and identified the somatic G12A KRAS mutation in one pilocytic astrocytoma.
  • Analyzed astrocytomas without mutations in Ras or neurofibromin may harbor mutations in other proteins of this pathway leading to hyperactive Ras signaling.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Mutation / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins p21(ras) / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17712732.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.6.5.2 / HRAS protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


100. Terasaki M, Tokutomi T, Shigemori M: Salvage therapy with temozolomide for recurrent or progressive high-grade gliomas refractory to ACNU [1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride]. Mol Med Rep; 2009 May-Jun;2(3):417-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy with temozolomide for recurrent or progressive high-grade gliomas refractory to ACNU [1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride].
  • This study aimed to determine safety, response rate, toxicity and 6-month progression-free survival (PFS) by using temozolomide (TMZ) as salvage chemotherapy for 25 adults with recurrent or progressive high-grade gliomas (HGGs) who failed 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) therapy.
  • Twenty-six patients with recurrent or progressive ACNU refractory HGG, including 12 with glioblastoma (GBM) and 13 with anaplastic astrocytoma (AA) were evaluated in a prospective study of temozolomide salvage chemotherapy.
  • The best response to chemotherapy had no impact on the duration of disease control.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21475844.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement